ADELINE MANGWA: Open Payments
NPI 1497015283 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,153 in 99 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $899 · 2025 $3,153
Food & beverage: $2,362Travel & lodging: $792
| Company | Payments | Amount |
|---|---|---|
| Neuronetics, Inc. | 5 | $987 |
| ABBVIE INC. | 16 | $436 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $393 |
| Janssen Pharmaceuticals, Inc | 8 | $308 |
| Otsuka America Pharmaceutical, Inc. | 6 | $211 |
| Vanda Pharmaceuticals Inc. | 9 | $192 |
| Lundbeck LLC | 8 | $168 |
| Alkermes, Inc. | 12 | $151 |
| Teva Pharmaceuticals USA, Inc. | 6 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
Products named: NEUROSTAR TMS THERAPY SYSTEM, VRAYLAR, CAPLYTA, REXULTI, SPRAVATO, ARISTADA, INVEGA SUSTENNA, UZEDY.
Industry payments across MD — which companies pay providers there.
